券商评级摘要 - SentinelOne目前的平均券商推荐评级为1.77，介于强力买入和买入之间，该评级基于35家券商的建议计算得出[2] - 在构成当前评级的35份建议中，有21份为强力买入，占比60%，另有1份买入建议，占比2.9%[2] 券商评级可靠性分析 - 研究表明，券商推荐在帮助投资者选择具有最大价格上涨潜力的股票方面成功率很低[5] - 券商对其覆盖股票的利益关系常导致分析师给出强烈的正面评级偏见，研究显示券商发布强力卖出与强力买入推荐的比例为1比5[6] - 券商评级可能并非最新，因其更新不及时[12] Zacks评级系统分析 - Zacks评级是一个基于盈利预测修正的定量模型，将股票分为5类，从排名第1（强力买入）到排名第5（强力卖出）[8][9] - 短期股价变动与盈利预测修正趋势高度相关，Zacks评级能及时反映分析师对盈利预测的修正[11][12] - 该工具在所有覆盖股票中按比例分配不同等级，始终保持其分配五个等级之间的平衡[11] SentinelOne投资前景 - 对于SentinelOne，本年度Zacks共识预期在过去一个月里下降了1%，至0.19美元[13] - 分析师对公司盈利前景的悲观情绪日益增强，这可能导致该股在短期内下跌[13] - 基于盈利预测的相关变化，SentinelOne获得了Zacks排名第4（卖出）的评级[14]

HIVE Digital Technologies (HIVE) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.I ...

A downtrend has been apparent in HeartSciences Inc. (HSCS) lately. While the stock has lost 8.3% over the past two weeks, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the stock find support.The formation of a hammer pattern is considered a technical indication of nearing a bottom with likely subsiding of selling pressure. But this is not the only factor that makes a bullish ca ...

Alkermes (ALKS) closed the last trading session at $30.98, gaining 12.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $41.76 indicates a 34.8% upside potential.The average comprises 17 short-term price targets ranging from a low of $30.00 to a high of $54.00, with a standard deviation of $6.16. While the lowest estimate indicates a decline of 3.2% from the current price level, t ...

Teva Pharmaceutical Industries Ltd. (TEVA) closed the last trading session at $19.42, gaining 2.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $24.88 indicates a 28.1% upside potential.The average comprises eight short-term price targets ranging from a low of $20.00 to a high of $29.00, with a standard deviation of $2.53. While the lowest estimate indicates an increase of 3% fr ...

Shares of Monopar Therapeutics Inc. (MNPR) have gained 21.2% over the past four weeks to close the last trading session at $77.15, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $109.91 indicates a potential upside of 42.5%.The average comprises 11 short-term price targets ranging from a low of $85.00 to a high of $142.00, with a standard deviation of $17. While the lowest esti ...

Shares of Liquidia Technologies, Inc. (LQDA) have gained 6.7% over the past four weeks to close the last trading session at $24.44, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $36.89 indicates a potential upside of 50.9%.The mean estimate comprises nine short-term price targets with a standard deviation of $13.63. While the lowest estimate of $6.00 indicates a 75.5% decline ...

股价表现 - 公司股价在最近一个交易日大幅上涨19.5%，收于12.16美元，此次上涨伴随显著放量 [1] - 此次上涨扭转了公司股票在过去四周累计下跌9.1%的趋势 [1] 业绩与财务表现 - 公司公布的2025财年第三季度初步业绩强劲，初步形式收入超过1.25亿美元，主要由DefenCath销售额超过8500万美元所驱动 [2] - 公司上调了2025财年全年形式净收入指引至至少3.75亿美元，高于此前3.25亿至3.5亿美元的范围 [2] - 预计第三季度调整后税息折旧及摊销前利润为7000万美元，并预期从Melinta整合中获得3000万美元的运营协同效应 [2] - 预计年终现金余额约为1亿美元，显示财务灵活性改善 [2] - 市场预期公司即将公布的季度每股收益为0.48美元，同比增长1060%，预期收入为6955万美元，同比增长506.9% [3] 盈利预期与评级 - 市场对公司的季度每股收益共识预期在过去30天内上调了55.1% [4] - 公司股票目前的Zacks评级为2级（买入） [4] 行业比较 - 公司所属行业为Zacks医疗-生物医学和遗传学行业，同行业公司Legend Biotech在上一交易日上涨3%，收于32.91美元，但过去一个月回报为-6% [4] - Legend Biotech对即将公布报告的每股收益共识预期在过去一个月变化了+16.7%，至-0.08美元，较上年同期变化+76.5%，其当前Zacks评级为3级（持有） [5] 产品管线进展 - 公司战略管线取得进展，包括Rezzayo用于预防侵袭性真菌感染的后期研究正在进行中 [2]

股价表现与目标 - 公司股票在上一交易日收于9.22美元，过去四周上涨1.9% [1] - 华尔街分析师设定的平均目标价为15.5美元，意味着有68.1%的上涨潜力 [1] - 最低目标价13美元预示41%的涨幅，最乐观目标价20美元则预示116.9%的涨幅 [2] 分析师目标价分析 - 平均目标价基于8个短期预测，标准差为2.62美元，显示预测存在一定变异性 [2] - 分析师设定目标价的能力和公正性长期受到质疑，不应作为唯一投资决策依据 [3] - 尽管分析师深谙公司基本面，但为吸引投资者关注，其目标价可能过于乐观 [8] 盈利预测修正 - 分析师一致上调公司盈利预测是预示股价上涨的合理理由 [11] - 当前年度Zacks共识预期在过去一个月内上涨2.4%，且仅见上调未见下调 [12] - 盈利预测修正趋势与短期股价变动之间存在强相关性 [11] 投资评级与展望 - 公司目前获得Zacks排名第2级（买入），位列其追踪的4000多只股票的前20% [13] - 尽管共识目标价本身可能不可靠，但其暗示的股价运动方向是良好的参考指南 [14]

Shares of Serve Robotics Inc. (SERV) have gained 2.5% over the past four weeks to close the last trading session at $14.33, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $18.67 indicates a potential upside of 30.3%.The mean estimate comprises six short-term price targets with a standard deviation of $4.37. While the lowest estimate of $15.00 indicates a 4.7% increase from the ...